Donor Pericardial Interleukin and Apolipoprotein Levels May Predict the Outcome after Human Orthotopic Heart Transplantation

The proinflammatory cascade that is activated at the time of brain death plays a crucial role in organ procurement. Our aim of this study was to explore the relationship between the clinical outcome of orthotopic heart transplantation, as well as cytokine and apolipoprotein profiles of the pericardial fluid obtained at donation. Interleukin, adipokine and lipoprotein levels in the pericardial fluid, as well as clinical data of twenty donors after brain death, were investigated. Outcome variables included primary graft dysfunction, the need for posttransplantation mechanical cardiac support and International Society for Heart and Lung Transplantation grade ≥ 2R rejection. Hormone management and donor risk scores were also investigated. Lower levels of IL-6 were observed in primary graft dysfunction (median: 36.72 [IQR: 19.47–62.90] versus 183.67 [41.21–452.56]; p = 0.029) and in the need for mechanical cardiac support (44.12 [20.12–85.70] versus 247.13 [38.51–510.38]; p = 0.043). Rejection was associated with lower ApoAII (p = 0.021), ApoB100 (p = 0.032) and ApoM levels (p = 0.025). Lower adipsin levels were detected in those patients receiving desmopressin (p = 0.037); moreover, lower leptin levels were found in those patients receiving glucocorticoid therapy (p = 0.045), and higher T3 levels were found in those patients treated with L-thyroxine (p = 0.047) compared to those patients not receiving these hormone replacement therapies. IL-5 levels were significantly associated with UNOS-D score (p = 0.004), Heart Donor Score (HDS) and Adapted HDS (p < 0.001). The monitoring of immunological and metabolic changes in donors after brain death may help in the prediction of potential complications after heart transplantation, thus potentially optimizing donor heart allocation.

[1]  H. Copeland,et al.  Donor heart selection: Evidence-based guidelines for providers. , 2022, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[2]  J. Copeland,et al.  Donor Utilization in the Recent Era: Effect of Sex, Drugs, and Increased Risk , 2022, Circulation. Heart failure.

[3]  D. Kaye,et al.  Vasoplegia Following Orthotopic Heart Transplantation: Prevalence, Predictors and Clinical Outcomes. , 2021, Journal of cardiac failure.

[4]  B. Merkely,et al.  Endocrine Management and Hormone Replacement Therapy in Cardiac Donor Management: A Retrospective Observational Study. , 2021, Transplantation proceedings.

[5]  C. Selzman,et al.  Circulating and Myocardial Cytokines Predict Cardiac Structural and Functional Improvement in Patients With Heart Failure Undergoing Mechanical Circulatory Support , 2021, Journal of the American Heart Association.

[6]  G. Guyatt,et al.  Incidence and impact of primary graft dysfunction in adult heart transplant recipients: A systematic review and meta-analysis. , 2021, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  G. Balasubramani,et al.  Donor Left Ventricular Function Assessed by Echocardiographic Strain is a Novel Predictor of Primary Graft Failure After Orthotopic Heart Transplantation. , 2021, Journal of cardiothoracic and vascular anesthesia.

[8]  A. Kaider,et al.  The adapted Heart Donor Score , 2021, Transplant international : official journal of the European Society for Organ Transplantation.

[9]  B. Merkely,et al.  Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure , 2020, Cardiovascular Diabetology.

[10]  K. Khush,et al.  The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult heart transplantation report-2020; focus on deceased donor characteristics. , 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  J. Dumfarth,et al.  Transplanting Marginal Organs in the Era of Modern Machine Perfusion and Advanced Organ Monitoring , 2020, Frontiers in Immunology.

[12]  A. Tirosh,et al.  Donor thyroid hormone therapy is associated with an increased risk of graft dysfunction after heart transplantation , 2020, Clinical transplantation.

[13]  J. Copeland,et al.  Donor heart and lung procurement: A consensus statement. , 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[14]  Jae-myeong Lee,et al.  Medical Management of Brain-Dead Organ Donors , 2019, Acute and critical care.

[15]  C. Leitão,et al.  Brain Death-Induced Inflammatory Activity is Similar to Sepsis-Induced Cytokine Release , 2018, Cell transplantation.

[16]  B. Meiser,et al.  The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth adult lung and heart-lung transplant report-2018; Focus theme: Multiorgan Transplantation. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[17]  M. Swaminathan,et al.  Primary graft dysfunction after heart transplantation: Incidence, trends, and associated risk factors , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  M. Acker,et al.  Report From the American Society of Transplantation Conference on Donor Heart Selection in Adult Cardiac Transplantation in the United States , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  L. Lund,et al.  The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report-2017; Focus Theme: Allograft ischemic time. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[20]  O. Millán,et al.  Cytokine-based immune monitoring. , 2016, Clinical biochemistry.

[21]  M. Slaughter,et al.  Heart Transplant Survival Based on Recipient and Donor Risk Scoring: A UNOS Database Analysis , 2015, ASAIO journal.

[22]  N. Rose,et al.  The varying faces of IL-6: From cardiac protection to cardiac failure. , 2015, Cytokine.

[23]  S. Russell,et al.  Report from a consensus conference on primary graft dysfunction after cardiac transplantation. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[24]  Eugene Kim,et al.  Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. , 2013, International journal of epidemiology.

[25]  R. Dhar,et al.  Comparison of high- and low-dose corticosteroid regimens for organ donor management. , 2013, Journal of critical care.

[26]  Daryl A Jones,et al.  A systematic review and meta-analysis of clinical trials of thyroid hormone administration to brain dead potential organ donors* , 2012, Critical care medicine.

[27]  B. Meiser,et al.  Donor scoring system for heart transplantation and the impact on patient survival. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[28]  Mary E. Ziegler,et al.  Apolipoprotein A1 and C-Terminal Fragment of &agr;-1 Antichymotrypsin Are Candidate Plasma Biomarkers Associated With Acute Renal Allograft Rejection , 2011, Transplantation.

[29]  K. Tsuchiya,et al.  MafA is a Key Molecule in Glucose and Energy Balance in the Central Nervous System and Peripheral Organs , 2011, International journal of biomedical science : IJBS.

[30]  G. D’Ancona,et al.  Primary graft failure after heart transplantation: the importance of donor pharmacological management. , 2010, Transplantation proceedings.

[31]  Simon A. Jones,et al.  Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-61 , 2005, The Journal of Immunology.

[32]  R. Bolli,et al.  IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. , 2004, Cardiovascular research.

[33]  P. Björntorp,et al.  Effects of glucocorticoids on leptin levels and eating behaviour in women , 2003, Journal of internal medicine.

[34]  H. Scheld,et al.  The interleukin-6/interleukin-6-receptor system is activated in donor hearts. , 2002, Journal of the American College of Cardiology.

[35]  M. Taal,et al.  Activation of the Heart by Donor Brain Death Accelerates Acute Rejection After Transplantation , 2000, Circulation.